Clinical Research Directory

Inclusion Criteria: * Subject requires an implant or replacement a of dual chamber pacemaker * Stable (at least one month) hypertension treatment with at least 1 anti-hypertensive drug, which is anticipated to be maintained for 7 months. * Average day time (7AM-10PM) ambulatory systolic blood pressure ≥ 130 mmHg and office blood pressure ≥140 mmHg. * Subject lives in the proximity of the study center, which permits compliance with study visits for at least 7 months. Exclusion Criteria: * Known secondary cause of HTN. * Average ambulatory or office systolic BP \> 195 mmHg. * Permanent atrial fibrillation. * History of significant paroxysmal atrial fibrillation/flutter burden (defined as \>25% of beats). * Cardiac ejection fraction \<50%. * Symptoms of heart failure, NYHA Class II or greater. * Hypertrophic cardiomyopathy, restrictive cardiomyopathy or inter-ventricular septal thickness ≥ 15 mm. * Subject is on dialysis. * Subject has an estimated Glomerular Filtration Rate \< 30 ml/min/1.73 m² * Prior neurological events (stroke or TIA) within the past year or events at a prior time that has resulted in residual neurologic deficit. * Carotid artery disease. * Known autonomic dysfunction. * History of clinically significant untreated ventricular tachyarrhythmia or has experienced sudden death. * Previous active device-based treatment for HTN. * Existing implant, other than a pacemaker that needs replacing. * Subject is or has the possibility of becoming pregnant and is unwilling of contraception during the study. * Subject is unwilling or cannot provide Informed Consent